Effects and mechanisms of curcumin and basil polysaccharide on the invasion of SKOV3 cells and dendritic cells

Molecular Medicine Reports

Volumn 8, Issue 5, 2013, Pages 1580-1586

  Lv, Jing ^a   Shao, Qianqian ^a   Wang, Huayang ^a   Shi, Huan ^a   Wang, Ting ^a,b   Gao, Wenjuan ^a   Song, Bingfeng ^a   Zheng, Guangjuan ^b   Kong, Beihua ^a   Qu, Xun ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Cell invasion; Curcumin; Dendritic cells; Ocimum basilicum; Ovarian cancer

Indexed keywords

CD44V ANTIGEN; CURCUMIN; GELATINASE B; MESSENGER RNA; OCIMUM BASILICUM EXTRACT; OSTEOPONTIN;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL INVASION; CELL MATURATION; DENDRITIC CELL; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; OVARY CANCER; PROTEIN EXPRESSION; SKOV 3 CELL; TUMOR INVASION;

ANIMALS; ANTIGENS, CD44; BLOTTING, WESTERN; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CURCUMIN; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; MATRIX METALLOPROTEINASE 9; MICE; MONOCYTES; NEOPLASM INVASIVENESS; OCIMUM BASILICUM; OSTEOPONTIN; OVARIAN NEOPLASMS; PLANT EXTRACTS; POLYSACCHARIDES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84885092904     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1695     Document Type: Article

References (39)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
2. Amati L, Pepe M, Passeri ME, Mastronardi ML, Jirillo E and Covelli V: Toll-like receptor signaling mechanisms involved in dendritic cell activation: potential therapeutic control of T cell polarization. Curr Pharm Des 12: 4247-4254, 2006.
3. Chu CS, Boyer J, Schullery DS, et al: Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunol Immunother 61: 629-641, 2012.
4. Triozzi PL, Khurram R, Aldrich WA, Walker MJ, Kim JA and Jaynes S: Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer. Cancer 89: 2646-2654, 2000.
5. Chakraborty G, Jain S, Behera R, et al: The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. Curr Mol Med 6: 819-830, 2006.
6. Bulfone-Paus S and Paus R: Osteopontin as a new player in mast cell biology. Eur J Immunol 38: 338-341, 2008.
7. Pagano PJ and Haurani MJ: Vascular cell locomotion: osteopontin, NADPH oxidase, and matrix metalloproteinase-9. Circ Res 98: 1453-1455, 2006.
8. Khan SA, Cook AC, Kappil M, et al: Enhanced cell surface CD44 variant (v6, v9) expression by osteopontin in breast cancer epithelial cells facilitates tumor cell migration: novel post-transcriptional, post-translational regulation. Clin Exp Metastasis 22: 663-673, 2005.
9. Chen YJ, Wei YY, Chen HT, et al: Osteopontin increases migration and MMP-9 up-regulation via alphavbeta3 integrin, FAK, ERK, and NF-kappaB-dependent pathway in human chondrosarcoma cells. J Cell Physiol 221: 98-108, 2009.
10. Desai B, Ma T, Zhu J and Chellaiah MA: Characterization of the expression of variant and standard CD44 in prostate cancer cells: identification of the possible molecular mechanism of CD44/MMP9 complex formation on the cell surface. J Cell Biochem 108: 272-284, 2009.
11. Yang G, Zhang Y, Wu J, et al: Osteopontin regulates growth and migration of human nasopharyngeal cancer cells. Mol Med Rep 4: 1169-1173, 2011.
12. Schulz G, Renkl AC, Seier A, Liaw L and Weiss JM: Regulated osteopontin expression by dendritic cells decisively affects their migratory capacity. J Invest Dermatol 128: 2541-2544, 2008.
13. Visintin I, Feng Z, Longton G, et al: Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 14: 1065-1072, 2008.
14. Bao LH, Sakaguchi H, Fujimoto J and Tamaya T: Osteopontin in metastatic lesions as a prognostic marker in ovarian cancers. J Biomed Sci 14: 373-381, 2007.
15. Zhang X, Zhang HQ, Zhu GH, et al: A novel mono-carbonyl analogue of curcumin induces apoptosis in ovarian carcinoma cells via endoplasmic reticulum stress and reactive oxygen species production. Mol Med Rep 5: 739-744, 2012.
16. Selvendiran K, Ahmed S, Dayton A, et al: HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition. Cancer Biol Ther 12: 837-845, 2011.
17. Sadzuka Y, Nagamine M, Toyooka T, Ibuki Y and Sonobe T: Beneficial effects of curcumin on antitumor activity and adverse reactions of doxorubicin. Int J Pharm 432: 42-49, 2012.
18. Luo F, Song X, Zhang Y and Chu Y: Low-dose curcumin leads to the inhibition of tumor growth via enhancing CTL-mediated antitumor immunity. Int Immunopharmacol 11: 1234-1240, 2011.
19. Bhattacharyya S, Md Sakib Hossain D, Mohanty S, et al: Curcumin reverses T cell-mediated adaptive immune dysfunctions in tumor-bearing hosts. Cell Mol Immunol 7: 306-315, 2010.
20. Badisa RB, Tzakou O, Couladis M and Pilarinou E: Cytotoxic activities of some Greek Labiatae herbs. Phytother Res 17: 472-476, 2003.
21. Xia L, Zheng G, Zhou H, et al: The application of BPS in the preparing of anti-metastasis therapies. P.R. China Patent CN1498625. Filed, November 8, 2002; Issued, May 26, 2004 (In Chinese).
22. Renkl AC, Wussler J, Ahrens T, et al: Osteopontin functionally activates dendritic cells and induces their differentiation toward a Th1-polarizing phenotype. Blood 106: 946-955, 2005.
23. Ji C, Cao C, Lu S, et al: Curcumin attenuates EGF-induced AQP3 up-regulation and cell migration in human ovarian cancer cells. Cancer Chemother Pharmacol 62: 857-865, 2008.
24. Seo JH, Jeong KJ, Oh WJ, et al: Lysophosphatidic acid induces STAT3 phosphorylation and ovarian cancer cell motility: their inhibition by curcumin. Cancer lett 288: 50-56, 2010.
25. Shirley SA, Montpetit AJ, Lockey RF and Mohapatra SS: Curcumin prevents human dendritic cell response to immune stimulants. Biochem Biophys Res Commun 374: 431-436, 2008.
26. Tilli TM, Franco VF, Robbs BK, et al: Osteopontin-c splicing isoform contributes to ovarian cancer progression. Mol Cancer Res 9: 280-293, 2011.
27. Zhang W, Yang HC, Wang Q, et al: Clinical value of combined detection of serum matrix metalloproteinase-9, heparanase, and cathepsin for determining ovarian cancer invasion and metastasis. Anticancer Res 31: 3423-3428, 2011.
28. Lin YG, Kunnumakkara AB, Nair A, et al: Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res 13: 3423-3430, 2007.
29. Watson JL, Greenshields A, Hill R, et al: Curcumin-induced apoptosis in ovarian carcinoma cells is p53-independent and involves p38 mitogen-activated protein kinase activation and downregulation of Bcl-2 and survivin expression and Akt signaling. Mol Carcinog 49: 13-24, 2010.
30. Ganta S, Devalapally H and Amiji M: Curcumin enhances oral bioavailability and anti-tumor therapeutic efficacy of paclitaxel upon administration in nanoemulsion formulation. J Pharm Sci 99: 4630-4641, 2010.
31. Rogers NM, Kireta S and Coates PT: Curcumin induces maturation-arrested dendritic cells that expand regulatory T cells in vitro and in vivo. Clin Exp Immunol 162: 460-473, 2010.
32. Cong Y, Wang L, Konrad A, Schoeb T and Elson CO: Curcumin induces the tolerogenic dendritic cell that promotes differentiation of intestine-protective regulatory T cells. Eur J Immunol 39: 3134-3146, 2009.
33. Orian-Rousseau V: CD44, a therapeutic target for metastasising tumours. Eur J Cancer 46: 1271-1277, 2010.
34. Samanna V, Wei H, Ego-Osuala D and Chellaiah MA: Alpha-V-dependent outside-in signaling is required for the regulation of CD44 surface expression, MMP-2 secretion, and cell migration by osteopontin in human melanoma cells. Exp Cell Res 312: 2214-2230, 2006.
35. Jijiwa M, Demir H, Gupta S, et al: CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway. PloS One 6: e24217, 2011.
36. Chagan-Yasutan H, Tsukasaki K, Takahashi Y, et al: Involvement of osteopontin and its signaling molecule CD44 in clinicopathological features of adult T cell leukemia. Leuk Res 35: 1484-1490, 2011.
37. Philip S and Kundu GC: Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha/IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways. J Biol Chem 278: 14487-14497, 2003.
38. Bagnoli F, Oliveira VM, Silva MA, Taromaru GC, Rinaldi JF and Aoki T: The interaction between aromatase, metalloproteinase 2,9 and CD44 in breast cancer. Rev Assoc Med Bras 56: 472-477, 2010.
39. Yu Q and Stamenkovic I: Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 14: 163-176, 2000.